GILD:NASDAQGilead Sciences, Inc. Analysis
Data as of 2026-09-05 - not real-time
$151.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Gilead Sciences, Inc. is priced at $151.00 and its moving averages line up in bullish order, the shorter sitting above the longer. Across the trailing 30 sessions it gained 16.8%. Momentum indicators put RSI at 67.7 (approaching overbought) with MACD reading bullish. Price has been bracketed by support at $131.61 and resistance at $152.55.
Valuation screens as fair: a P/E of 15.3 sits below the sector average of 30.6. Sell-side targets cluster 4.2% above the current quote. Revenue is growing at 10.2% on a -10.6% profit margin. The 2.17% dividend yield looks covered by current payout levels.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 25.8%, a beta of 0.34 and a maximum drawdown of 22.0%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 2/10 conviction over the longer horizon.
Valuation screens as fair: a P/E of 15.3 sits below the sector average of 30.6. Sell-side targets cluster 4.2% above the current quote. Revenue is growing at 10.2% on a -10.6% profit margin. The 2.17% dividend yield looks covered by current payout levels.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 25.8%, a beta of 0.34 and a maximum drawdown of 22.0%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 2/10 conviction over the longer horizon.
Top Market Events
Gilead delivers strongest Q2 base business growth in 3 years, raises full-year HIV guidance, and showcases rapid uptake...Biopharmaceutical company Gilead Sciences NASDAQ:GILD reported Q2 CY2026 results topping the market’s revenue...Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 5/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 134.36
- MACD momentum is positive
Medium Term
1–3 yearsPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 15.3 versus sector average of 30.6
- Trading above the 200-day average of 134.36
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 15.3 versus sector average of 30.6
- Negative profit margin of -10.6%
- Negative return on equity of -20.7%
Key Metrics & Analysis
Financial Health
Revenue Growth10.20%
Profit Margin-10.64%
P/E Ratio15.3
ROE-20.68%
ROA14.09%
Debt/Equity223.47
P/B Ratio15.8
Op. Cash Flow$13.6B
Free Cash Flow$9.8B
Industry P/E30.6
Technical Analysis
TrendBullish
RSI67.7
Support$131.61
Resistance$152.55
MA 20$144.35
MA 50$136.60
MA 200$134.36
MACDBullish
VolumeStable
Fear & Greed Index95.48
Valuation
Fair Value$135.90
Target Price$157.41
Upside/Downside4.25%
GradeFair
TypeBlend
Dividend Yield2.17%
Risk Assessment
Beta0.34
Volatility25.76%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.